Proceedings Of The Annual General Meeting.
Proceedings of the Annual General Meeting.11-08-2017
Press Release / Media Release
Zydus receives tentative approval from the USFDA for Mesalamine Suppositories for rectal use.Cadila Healthcare Q1 profit falls 65% to Rs138 crore
Cadila Healthcare reported a 65.26% decline in its consolidated net profit at Rs138.4 crore for the first quarter ended June 30Outcome of Board Meeting
Unaudited Financial Results for the quarter ended on June 30, 2017.Will recall of tablets impact Cadila?
Zydus Pharmaceuticals US Inc is recalling from the American market over 3.31 lakh bottles of Divalproex Sodium delayed release tablets used for the treatment of seizures and manic episodes in...Father-son duo turn family drug firm Cadila into world beater
Cadila Healthcare, run by Pankaj and son Shravil Patel, earned the title of top generic drug manufacturer, despite regulatory scrutiny and withering competition in the USZydus Cadila gets USFDA nod for high blood pressure, heart disorder drug
The hypertension drug is used to treat chest pain, certain heart rhythm disordersPress Release / Media Release
Zydus receives final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP.